摘要
探讨头孢布烯对肺癌合并肺内感染的临床效果。采用开放式，符合选择条件者３０例，口服头孢布烯２００ｍ ｇ 每日２次，连服７ｄ。于用药前后均检查痰细菌学以判定结果。结果表明，绝大部分患者用药后第３ 天症状、体征好转，第７天有１３例为显效，１５ 例有效，总有效率为９３．３％ （２８／３０）。头孢布烯对治疗肺癌合并肺内感染疗效高，副作用轻微，可于临床普遍使用。
To inquire into the clinical effects of ceftibuten in treatment of pulmonary infections with pulmonary carcinoma. An open study was adopted, 30 patients accorded with choosen conditions. Oral ceftibuten were in a regime of 200 mg bid for 7d. To evaluate the results, bacteria were inspected before and after used ceftibuten. Most patients′ symptoms and signs were relived after 3d of dosing, obvious effects occured 13 patients after 7d, 15 patients were effective, total effective rate was 93.3% (28/30). Ceftibuten is very effective in treatment of pulmonary infections with pulmonary carcinoma but with less side effects. Ceftibuten will be used extensively in clinicals.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1999年第5期368-370,共3页
Chinese Journal of Antibiotics
关键词
头孢布烯
肺内感染
肺肿瘤
并发症
Ceftibuten
Pulmonary infections with pulmonary carcinoma
